Form D · Pharmaceuticals
CYTRX CORP
Los Angeles, CA · CIK 0000799698
Offering snapshot reported Jul 28, 2022 · SEC filing
- Reported sold
- $8.24M Offering amount: $18.2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 13, 2021 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 28, 2022 | Amendment | $8,240,000 | $0vs Jul 29, 2021 | 1 | SEC filing |
| Jul 29, 2021 | Initial | $8,240,000 | No comparison | 1 | SEC filing |
| Feb 10, 2016 | Initial | $1,291,500 | No comparison | 2 | SEC filing |
| May 4, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 21, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $1.28M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-408110
Represents 8,240 shares of Series C 10.00% Convertible Preferred Stock at $1,000 per share and preferred investment options ("PIOs") to purchase up to 11,363,637 shares of common stock, exercise price of $0.88 per share, initially sold on 7/13/2021.
Consists of: $600,000 cash fee (6% of the aggregate gross proceeds), $75,000 in reimbursable non-accountable expenses, $6,600 in escrow fees and $600,000, the maximum additional cash fee payable to the Agent, subject to the exercise of PIOs for cash.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Jul 28, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joel Caldwell | Director |
| John Caloz | Executive |
| Anita Chawla | Director |
| Cary Claiborne | Director |
| Cheryl Cohen | Director |
| D Haen | Executive |
| Louis J Ignarro | Director |
| Steven Kreigsman | Director, Executive |
| Steven A Kriegsman | Director, Executive |
| Benjamin Levin | Executive |
| Joseph Rubinfeld | Director |
| Eric Selter | Director |
| Jennifer Simpson | Director |
| Stephen Snowdy | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:Los Angeles, CA, 90049